- CohBar Inc CWBR has updated the timing for releasing Phase 1a/1b trial data of CB4211 for the potential treatment of nonalcoholic steatohepatitis (NASH) and obesity.
- The process of data entry and final validation, which must be concluded before database lock, is ongoing.
- Once the database is locked, external biostatisticians will have access to the unblinded data from the study, enabling them to perform the data analysis and generate the final output.
- The company currently expects to release topline data before Labor Day 2021.
- In Q1 2021 earnings release, the company expected the data in early July 2021.
- Price Action: CWBR shares are down 17.4% at $1.14 during the market session on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
